000			03419nam a22003497a 4500
999			_c12287 _d12287
001			OB 2021 0005
003			PILC
005			20240720153244.0
008			220428b xxu||||| |||| 00| 0 eng d
040			_beng _cFEU-NRMF MEDICAL LIBRARY _erda
041			_aenglish
050			_aOB 2021 0005
245			_aA Randomized controlled trial comparing the efficacy of a seven day regimen of co-amoxiclav versus a single dose second generation cephalosporin (cefoxitin) as prophylactic antibiotic therapy for third and fourth degree perineal lacerations among post-partum patients in a tertiary medical center / _cSamantha Quennie Wanasen-Razon; Lylah D. Reyes; Jennifer Co.
260			_aFairview, Quezon City: _bDepartment of Obstetrics and Gynecology, FEU-NRMF, _c2021.
300			_a46 pages: _billustrations, tables; _c(in folder) + _ewith flash drive (soft copy).
336			_2rdacontent _atext
337			_2rdamedia _aunmediated
338			_2rdacarrier _avolume
504			_aIncludes appendices and bibliographical references.
520			_aAbstract: Episiotomy is a common obstetrical practice in the Philippines. However, particularly from midline episiotomy, a third- or fourth degree extension may not be prevented. This predisposes the episiotomy site to infection and wound breakdown due to bacterial contamination from the rectum. Compare the efficacy of single dose cefoxitin versus seven-day regimen of Co-amoxiclav in preventing wound infection of third- or fourth degree perineal tears among women who had episiotomy during vaginal delivery. Included were 64 women, 18 to 35 years old, who delivered vaginally and sustained a third or fourth degree laceration during episiotomy. Participants were randomly allocated to group A: single dose of Cefoxitin, 1 gram intravenous, given 30 minutes after delivery and group B: Co-amoxiclav, 750 mg twice a day for seven days postdelivery. Assessment for wound infection, pain/discomfort and adverse event rates as well as mean pain, REEDA scores and length of hospital stay between two groups were done right after episiorrphy, on the day of discharge and seven days after discharge. Wound infection, pain and discomfort were not noted for both treatment arms during the seven-day follow up period. The mean pain and REEDA scores tend to be higher among the participants in the co-amoxiclav group. There was also more adverse effects, such as nausea, dizziness and vomiting noted among those participants in the co-amoxiclav than in the cefoxitin group. Length of hospital stay ranged from 2 to 4 days with a mean of 2.98. Although, no statistically significant differences were noted between the two groups. Seven-day oral co-amoxiclav is comparable with single dose intravenous cefoxitin in preventing wound infection from third- or fourth degree perineal tears as well as safety. Thereby, compared to oral co-amoxiclav regimen, single dose cefoxitin is the cost-beneficial option among women with episiotomies having extension.
521			_aRESDOG
650			_acefoxitin
650			_aco-amoxiclav
650			_aepisiotomy
650			_athird forth degree perineal laceration
650			_aanal sphincter injury
650			_awound dehiscence
700			_aWanasen-Razon, Samantha Quennie, MD. _eprincipal investigator
700			_aReyes, Lylah D., MD. _eco-author
700			_aCo, Jennifer, MD. _eco-author
942			_2lcc _cRU